Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT-246475 single-dose subcutaneous study in adults with stable coronary artery disease
2017-003332-36Phase 2Completed
- Sponsor
- Idorsia
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of selatogrel in coronary arteriosclerosis (5 arms), sponsored by Idorsia. Primary endpoint: Pharmacodynamic response based on VerifyNow P2Y12 Reaction Units. Started Oct 2017; status: completed.
02
Drugs
selatogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2017-003332-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003332-36.